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ABSTRACT
Eukaryotic pathogens (e.g. Plasmodium,  Leishmania,  Trypanosomes, etc.) are a major source of 
morbidity and mortality worldwide. In Africa, one of the most impacted continents, they cause 
millions of deaths and constitute an immense economic burden. While the genome sequence of 
several of these organisms is now available, the biological functions of more than half  of their 
proteins are still unknown. This is a serious issue for bringing to the foreground the expected new 
therapeutic targets. In this context, the identification of protein domains is a key step to improve 
the functional annotation of the proteins.
However, several domains are missed in eukaryotic pathogens because of the high phylogenetic 
distance of these organisms from the classical eukaryote models. We recently proposed a method, 
Co-Occurrence  Domain  Detection  (CODD),  that  improves  the  sensitivity  of  Pfam  domain 
detection by exploiting the tendency of domains to appear preferentially with a few other favorite 
domains in a protein.
In this paper, we present EuPathDomains (http://www.atgc-montpellier.fr/EuPathDomains/), an 
extended  database  of  protein  domains  belonging  to  ten  major  eukaryotic  human pathogens. 
EuPathDomains gathers known and new domains detected by CODD, along with the associated 
confidence measurements and the GO annotations that can be deduced from the new domains. 
This  database  significantly  extends  the  Pfam  domain  coverage  of  all  selected  genomes,  by 
proposing new occurrences of domains as well as new domain families that have never been 
reported  before.  For  example,  with  a  false  discovery  rate  lower  than  20%,  EuPathDomains 
increases the number of detected domains by 13% in Toxoplasma gondii genome and up to 28% 
in  Cryptospordium parvum,  and the total number of domain families by 10% in  Plasmodium 
falciparum and up to 16% in Cryptospordium parvum genome. The database can be queried by 
protein names, domain identifiers, Pfam or Interpro identifiers, or organisms, and should become 
a valuable resource to decipher the protein functions of eukaryotic pathogens.
Keywords: Pathogens, protein domains, functional annotations, Pfam, HMMs, database.
Introduction
Pathogenic eukaryotes belong to several distinct phylogenetic lineages causing a wide variety of 
host  infections.  They have evolved the  ability  to  infect  a  range of  hosts,  including humans,  
animals  and  plants  [1].  Despite  the  availability  of  the  complete  genome  of  many  of  these  
organisms, their exact infection mechanisms and invasion strategies, as well as the function of 
more than 50% of their proteins, are still under investigation. This is mainly due to their high 
phylogenetic  distance  from  the  classical  model  organisms,  as  well  as  to  their  evolutionary  
mechanisms that are quite different from those envisioned in classical models of evolution due to 
the  co-evolution of  host  and pathogens and the development  of  both systems in an ongoing 
process  [2].  In  fact,  parasites  have  evolved a  variety  of  mechanisms to  evade  host  immune 
recognition and elimination. Such evolution is a direct consequence of the fact that they live at  
the expense of, and are dependent on, host tissues for long periods during their life cycles [3].  
This contributed to the development of new gene functions and changes in the parasite’s genome 
repertoire, occurring through gene acquisition and deletion [4].
Among  the  relevant  annotations  that  can  be  attributed  to  a  protein,  domains  occupy  a  key 
position. Protein domains are sequential and structural motifs that are found independently in 
different proteins and in different combinations and, as such, seem to be functional subunits of 
proteins  above the raw amino acid sequence level  [5].  Protein domain composition provides 
strong clues for the protein function.  Indeed, two thirds of mono-domain proteins having the 
same domain also have the same functions. Likewise, 35% of multidomain proteins having one 
common domain present similar functions, while this rate increases to 80% when they share two  
common domains  [6].  Several  approaches and databases  have been  developed to  define  and 
identify domains. One of the most widely used domain scheme is the Pfam database [7], which is  
a collection of protein domain and families. Each family in Pfam is represented by a multiple 
sequence alignment and a profile Hidden Markov Model  (profile HMM) [8].  The Pfam 23.0 
release offers a large collection of 10 340 protein domains.
When analyzing a new sequence, each Pfam HMM is used to compute a score measuring the 
similarity between the sequence and the domain. If the score is above a given threshold provided 
by Pfam (each domain has a different score threshold), then the presence of the domain can be 
asserted in the protein. However, applied to divergent proteins, this strategy may miss several 
domains. This is the case for all eukaryotic pathogens, where no Pfam domains are detected in  
half  or  even more of their  proteins.  While the Pfam domain coverage of the classical  model 
organisms is 73% on average for all organisms (Table 1), this proportion varies for eukaryotic 
pathogens from 38%, (for Trypanosoma brucei) to 53% (for Plasmodium falciparum). Although 
this situation may be explained by the existence of genes that are unique to these organisms or  
specific  to  a  parasitic  life  style,  it  is  further  exacerbated  by  the  high  evolutionary  distance 
between these organisms and the other  organisms used as  model  Eukaryotes—such as yeast, 
worms, arabidopsis, drosophila and human [9]—, which makes homology detection particularly  
difficult.  
We recently proposed a method named CODD that  increases the sensitivity of Pfam domain 
detection in divergent proteins while controlling the false discovery rate (FDR) of the predictions 
[10].   Our  method  makes  use  of  the  well  known  tendency  of  protein  domains  to  appear  
preferentially with a few other favorite domains in proteins [11]. This enables us to certify the 
presence of domains below the recommended thresholds, on the basis of the presence of another  
domain in the same protein. Moreover, a shuffling procedure provides an estimate of the FDR 
associated with each prediction.
In  this  paper,  we  present  EuPathDomains,  an  extended database  of  known and  new protein 
domains identified by CODD on several major human pathogens (three Leishmania species, three 
Plasmodium species,  Toxoplasma  gondii,  Cryptospordium  parvum,  Giardia  lamblia and 
Trypanosoma  brucei)  selected  from  EupathDB  database  [12].  In  average,  EuPathDomains 
increases the number of domains in a proportion of ~10% in each genome (with an FDR<20%). 
Several new domains types were discovered, leading to an enrichment of 10% to 16% of the total 
number of domain families in each genome. Some of these domains are localized in proteins that 
had no known domain. In addition, these newly predicted domains induce new GO annotations 
for about 15% of the proteins within each of the studied organisms. EuPathDomains database 
provides all these predictions along with the already known domains and annotations in a friendly 
interface that allows easy browsing and querying.
In the following, we briefly describe the studied pathogens. We explain the principle of CODD 
and the shuffling procedure used to estimate the confidence (FDR) associated with the newly 
discovered domains.  We next  present  the  results  achieved on each  species,  and  describe  the 
EuPathDomains  database interface. Finally, as a case study, we emphasize the results obtained 
with the three selected Leishmania species.
Data and Methods
Pathogens included in EuPathDomains
One organism affecting humans, representative of each phylum of the EupathDB1 database was 
selected in this study [12]. These include L. major that causes leishmaniasis, three apicomplexans 
―P.  falciparum that  cause  malaria,  T.  gondii and  C.  parvum that  cause  respectively 
toxoplasmosis and a diarrheal illness called cryptosporidiosis ―, T. brucei that causes sleeping 
sickness, and G. lamblia that causes giardiasis. To allow comparative studies of close species,  
we  also  included  two  additional  Leishmania—L.  infantum  and  L.  braziliensis—and  two 
Plasmodium—P. vivax and P. yoelli.
Leishmania species. Infection by the insect-transmitted Leishmania parasites represents a serious 
global health problem for which there is no vaccine and few effective but toxic drugs [13]. Intra-
macrophagic protozoan leishmanies are single celled parasites that affect vertebrates including 
dogs and humans. At least 20  Leishmania species infect humans, and the spectrum of diseases 
that  they cause can be categorized broadly into three types: visceral leishmaniasis,  cutaneous 
leishmaniasis and mucocutaneous leishmaniasis.  Three different Leishmania species included in 
this study, i.e.;  L. major, L. infantum and L. braziliensis cause respectively cutaneous, visceral 
and mucocutanous leishmaniasis. These different Leishmania species contain each approximately 
8 000 protein coding genes, more than half of them do not have either GO annotation terms or 
known protein domains.
Plasmodium species. Plasmodium is a genus of parasitic protists. Infection by these organisms is 
known as malaria, which is one of the most devastating infectious diseases causing more than 1 
million deaths each year worldwide [14]. Currently, over 200 species of this genus are recognized 
and new species continue to be described. Over all these species, at least 5 infect humans. Various 
types of malaria are caused by the different species. P. falciparum causes the most severe disease 
and is responsible for nearly all malaria-related deaths. Other species cause debilitating diseases  
that are less severe but highly persistent. The parasite always has two hosts in its life cycle: a  
mosquito  vector  and  a  vertebrate  host.  In  this  work,  we  studied  three  different  plasmodium 
species: P. falciparum, P. vivax and P. yoelli. P. falciparum and P. vivax have approximately 5 500 
genes, while  P. yoelii genome contains about 7 720 genes. Nearly 50% proteins of each these 3 
species do not have any known Pfam domain.
Toxoplasma  gondii is a  single-celled  intracellular  parasite  that causes  a  disease  known  as 
toxoplasmosis.  Infections  by  T.  gondii are  highly  prevalent  in  humans  and  animals  and  the 
parasite is widely found throughout the world. The definitive host of T. gondii is the cat, but the 
parasite can be carried by many warm-blooded animals and cause severe and life-threatening  
disease in developing fetuses and immune-compromised individuals.  The majority of infected 
persons are asymptomatic due to their protective immune status [15]. T. gondi has about 8 102 
protein-coding genes, about 57% of them do not have any known Pfam domain.
Cryptosporidium parvum is a protozoan parasite that causes cryptosporidiosis, a disease affecting 
the mammalian intestinal tract and mainly characterized by a diarrheal illness. It is transmitted to 
the host via the fecal-oral route. Among healthy people, an acute self-limiting infection occurs,  
but  cryptosporidiosis  could  have  lethal  effects  on  immuno-compromised  individuals  (HIV 
infected, immuno-suppressed etc.). Cryptosporidiosis can be found worldwide, and in developing 
countries  8-19%  of  diarrheal  diseases  are  attributed  to  cryptosporidium [16].  Its  genomic 
sequence shows a small, compact genome of 9.1Mb with a simple organization containing only 
about 3 805 protein coding genes [17]. A total of 1 123 different Pfam domains are known on 
these proteins covering 51% of the whole genome.
Giardia  lamblia.  Giardiasis  is  a  parasitic  disease  caused  by  Giardia  species,  a  flagellated 
protozoan parasite that occupies the small intestine of numerous hosts including humans. Like 
Cryptosporidium, infection can occur due to ingestion of contaminated water or food and by the 
fecal-oral route. Depending on its life cycle stage (external dormant form versus ingested active 
form), two different parasite forms exist. Through protein-surface modification (with antigenic 
variation),  Giardia can  efficiently  evade  the  host’s  immune  defense  [18,  19].  Like  other 
diplomonads,  Giardia is  characterized  by  the  presence  of  two  nuclei.  Its  genome  was  only 
recently published and revealed a sequence of roughly 12Mb and about 5 000 protein-coding 
genes [20].
Trypanosoma brucei are obligate parasitic protists of mammals to which they are transmitted by 
an insect  vector  commonly called tsetse  fly.  They cause African trypanosomiasis,  commonly 
known as sleeping sickness. Its adaptation to different hosts, a common strategy among parasites, 
occurs through complex changes during its life cycle, and different parasite forms are known. A 
particular  feature  of  kinetoplastids,  in  comparison  with  other  eukaryotes,  is  a  mitochondrial  
genome-containing kinetoplast associated with the basal body of the flagellum. Its genome is 
composed of 11 chromosomes and contains nearly 9800 protein coding genes. About 62% of 
these genes do not have any known Pfam domain.
CODD: Co-occurrence based domain detection
CODD is a computational approach that increases the sensitivity of HMMs for domain detection,  
while controlling the false discovery rate (FDR) associated with the predictions [10].  CODD 
utilizes the tendency (observed through the three kingdoms of life) of many domain families to 
occur preferentially with a few other favorite families of proteins [21]. Thus, the presence of one  
domain in  a protein may be a strong clue for the presence of  another  one.  CODD uses  this  
tendency to warrant  the  presence  of  Pfam domains,  on  the  basis  of  the  presence  of  another 
domain in the same protein. The “validating domain” used for this purpose may be another Pfam 
domain or any other type of domain from the InterPro database [22].  CODD has been assessed 
both in Yeast and P. falciparum genomes [10]. It enabled the discovery of several hundreds new 
Pfam domain occurrences in  both organisms,  and contributed to  the enrichment of  the Gene 
Ontology (GO) annotation of their proteins.
The CODD principle is summarized in Figure 1. It involves five different steps:
1. The first step involves the identification of the Conditionally Dependent Pairs of domains 
(CDP), i.e. the domain pairs that tend to appear preferentially together in the same protein. The 
CDP list  is computed from the whole set of domain pairs observed in Uniprot proteins of all 
organisms.
2. The second step involves the identification of potential domains in the proteins of the 
target organism. This is done by searching the protein sequences against Pfam HMM profiles  
with a loose score threshold.
3. The third step is the certification procedure that uses the CDP list to certify the presence 
of potential domains thanks to the presence of other domains in the same protein.
4. A shuffling procedure is then used to estimate the confidence (False Discovery Rate or 
FDR) of the newly certified domains.
5. Finally, GO annotations are deduced from the newly discovered domains themselves and 
also from their combinations with others.
We further detail below how this general method has been implemented and used to build 
the EuPathDomains database.
Selecting the CDPs
The list of Conditionally Dependent Pairs (CDP) of domains was built from the whole set of  
domain pairs observed in UniProt proteins. These pairs must reveal a conditional dependence 
between a Pfam domain and an InterPro (Pfam or non-Pfam) domain, that is, the presence of the  
InterPro domain has to be a strong clue of the presence of the Pfam domain. For each pair, the 
number of proteins where both domains are present and where at least one domain is present is  
computed and used to measure the conditional dependence with a Fisher’s exact test. All pairs 
with a p-value < 1% are considered as conditionally dependent and are added into the CDP list.
Selecting the potential domains
The sets  of  potential  domains  were  inferred  from the  results  of  Pfam HMM searches  using 
HMMER software [23]. Given a set of proteins and an HMM, this tool computes a score that 
measures the similarity between each protein sequence and the domain modeled by the HMM. 
Additionally, this score can be used to compute an E-value estimate that represents the expected 
number of random sequences that would obtain a score above that achieved by the protein. Here,  
the set of potential domains of each protein was built by considering all HMM hits that differ  
from the already known Pfam domains and which have an E-value below a given permissive 
threshold  (e.g.  10).  This  E-value  threshold  is  chosen  to  be  much  less  conservative  than  the 
thresholds recommended by Pfam for each HMM.
Certification process
Each potential domain identified in the previous step is then queried for certification by another  
domain: if both domains are in the CDP list, the potential domain is certified. Three kinds of 
certifications are considered. The first  and most accurate one involves the certification of the 
potential domain by a known Pfam domain of the protein. A complementary solution is to certify 
the potential domain with an InterPro non-Pfam known domain. This allows us to increase the 
number  of  certifications.  However,  due  to  the  heterogeneity  of  the  InterPro  database,  the 
certifications  achieved in  this  way  may be  of  lower  quality  than  those  achieved  with  Pfam 
domains. The first two solutions certify domains solely in proteins where at least one domain is  
already known. To overcome this limitation, a third solution is to certify the potential domain by 
another potential domain of the protein. With this solution, all pairs of potential domains of the 
protein are enumerated, and if the pair belongs to the CDP list, the two domains are certified. Of  
course this procedure is more prone to false positives than the two others.
Estimating the number of false certifications
The  certification  procedure  allows  certifying  several  new  domains  among  all  the  potential 
domains identified in the proteins of the organism. One issue is then to estimate the proportion of 
false positives among these new domains. To this end, one estimates the probability of certifying 
a potential domain under the null hypothesis H0 that it has been randomly predicted. This is done 
through computer simulations, by shuffling the potential domains of all proteins. The certification 
procedure is applied to the shuffled domains, and the number of certified random domains is  
computed. The entire procedure is repeated several times (typically 1000 times) to get a reliable  
estimate of the expected number of domains this procedure would certify under H0, and this 
number is used to compute an estimate of the False Discovery Rate (FDR), i.e. the proportion of 
false positives in the new domains.
Gene Ontology annotations
The GO currently serves as the dominant approach for machine-legible functional annotation. GO 
is  a  controlled  and  structured  vocabulary  describing  three  aspects  of  gene  product  function: 
molecular function, biological process and cellular location. Attempts have been made to link the 
Pfam and InterPro domains with the terms of the GO. The pfam2go mapping associates a specific  
GO term with a Pfam domain if all proteins in which this domain is known share the term [24].  
Thanks to this mapping, when a new domain is certified in a protein, all terms associated with  
this domain (if any) can be transferred to the protein.
Protein function usually results from combination of domains rather than from a single one [24].  
Thus, we generated a second mapping that links whole domain combinations to GO annotations.  
This  second mapping  is  built  on  the  same principle  as  the  pfam2go mapping.  All  observed 
domain combinations of the Swiss-Prot  proteins  are enumerated.  Then,  for each combination 
present  in more than 10 proteins,  if  all  proteins in which the combination is  present  share a  
specific GO term, this term is assigned to the combination. As with the pfam2go mapping, this 
second mapping can be used to transfer new annotations to the protein in which a new domain is 
certified, if this domain forms an annotated combination with other known or certified domains.
Building the database
CODD was  applied  to  all  selected  and  above  described  organisms,  with  the  three  types  of  
certification (known Pfam, known non-Pfam, and potential Pfam). The set of known InterPro 
domains (Pfam and non Pfam) were downloaded from each organism’s specific database. For 
each organism, two E-value thresholds (typically 1 and 50) were used to identify the potential  
domains. This led to the construction of two different sets of potential domains of increasing size. 
CODD  was  run  on  each  set,  and  the  FDR  associated  with  the  certifications  achieved  was  
computed. High E-value thresholds usually allow more certifications, but with also higher FDRs. 
All certifications with an FDR below 20% were transferred to the EuPathDomains database. For 
each newly certified domain, the GO annotations that can be deduced from this domain, either  
solely or in combination with other known or newly certified domains, were also transferred to  
the database.
Results and discussion
The EuPathDomains database
EuPathDomains  (for  “Eukaryotic  Pathogens  Domains  database”)  is  freely  available  at 
http://www.atgc-montpellier.fr/EuPathDomains/. A friendly interface allows easy browsing and 
querying. The database can be queried in various ways, by protein names, domain IDs, Pfam or 
Interpro  identifiers, with  the  possibility  to  limit  the  search  on  an  organism  or  a  taxon 
(Plasmodiums, Apicomplexans, ...), and with a given FDR threshold. The result includes the list 
of proteins where the domain is already known and those where it has been predicted with the  
associated FDRs.
Figure  2  illustrates  a  typical  output  obtained  when  querying  for  the  L.  major protein 
LmjF36.4590. This figure shows the known domains for this protein as well as the predicted 
domains (with the domains that allowed their certification) and the related GO terms transferred 
to the protein. Some terms, such as “zinc ion binding” and “intracellular” are already known in 
the protein, but other annotations, such as “regulation of transcription, DNA dependent”, are new.
The database contains several hundred new Pfam domains in each species. Some of the newly  
predicted domains  have never  previously been seen in  these species.  Thus,  these  predictions 
enabled the set of known domain families in all studied organisms to be expanded. With a FDR 
below 20%, the database expands the set of domains between 13% in G. lamblia to up to 28% in 
C. parvum. It also expands the set of known domain families in each organism, between 10% in  
P. falciparum to up to 16% in C. parvum. Moreover, the newly discovered domains also provide 
new functional annotations for the proteins of the different species. The number of additional GO 
terms ranges from 302 in  G. lamblia to 684 in  T. brucei. Table 2 details the number of new 
domains  found in each species for the  three types of  certification.  The numbers  of new GO 
annotations that can be deduced from these domains are detailed in Table 3.
For example,  in  L. major, EuPathDomains contains a total of 719 new domains with a FDR 
below 20% (Table 2). This is an increase of 14% compared to the 5 216 already known Pfam 
domains  in  this  organism (only  one  occurrence  of  each  known/new  domain  per  protein  is 
considered here; Pfam release 23.0). Among these, 607 involve a new InterPro domain family in  
the protein.  The known Pfam domains allow for the certification of 385 out  of  the 719 new 
domains, the known non-Pfam domains 417, and the potential domains themselves 316 (several 
new domains are certified by 2 or the 3 types of certifications). As we can see,  the potential 
domains allow the certification of fewer domains than the known domains for a given FDR. This  
is not surprising, as these domains are potentially false. Hence, very low E-value thresholds are  
required to achieve low FDRs, which induce the selection of small amounts of potential domains. 
Moreover,  184  new  domain  types  were  discovered—i.e.  which  had  never  been  previously 
detected in L. major proteins—, an increase of 11% in the total number of domain types known in 
this parasite. With an FDR<20%, the newly discovered domains led to the identification of 466 
new GO terms (Table 3), representing 6% of the already known GO terms in L. major proteins. 
This allows us to propose GO annotations for 53 proteins without any annotation. Similar results 
were also achieved on the two other  Leishmania species (L. infantum and L. braziliensis;  see 
Supplementary Table S1 and S2, respectively).
Description of the newly discovered domains
We sought to characterize the specificities of the newly discovered domains, compared to the 
already known domains in each species. One of the first characteristics involves the length of the 
new domains. Usually, domains vary in length from about 25 to 500 amino acids. A comparison 
of the known and new Pfam domains shows that, on average, the newly certified domains are 
shorter than the already known domains (see Figure 3). This difference between known and new 
domains is not surprising, as short domains carry less information than longer ones, and are more 
difficult to detect, especially in divergent proteins. Thus, our certification procedure primarily 
enables recovery of these domains.
We next investigated the GO annotations provided by the newly predicted domains via Pfam2go 
mapping.  GO  annotations  provided  by  combination  of  several  domains  are  generally  more 
specific than those deduced from the presence of a single one. For previously annotated proteins,  
this enables the discovery of more accurate functions confirming the already known annotations.  
For example, the term « RNA polymerase II transcription factor activity », which catalyzes DNA 
transcription to synthesize precursors of mRNA and most snRNA and microRNA, is assigned to 
different Leishmania proteins by combining both predicted and already known domains.
For hypothetical or very poorly annotated proteins, two major cases are observed based on the  
level  of  annotation  of  the  newly  detected  domains.  On  the  one  hand,  the  new domains  are 
ascribed to no or poorly informative GO terms. In this case, no precise functional annotation can 
be deduced from the present work, but the structural categorization of the proteins is refined, 
providing clues for future functional inferences. On the other hand, newly detected domains can 
be  sufficiently  informative  and  have  accurate  GO  annotations,  which  are  transferred  to  the 
hypothetical or poorly annotated protein.
Next, we used the GOstat tool [25] to compare the GO annotations associated with the known and 
the newly certified domains according to the three axis of the Gene Ontology: molecular function,  
biological processes and cellular component. For each species, we uploaded in GOstat the set of 
newly discovered domain families, the set of known domain families, and the Pfam2go mapping. 
Then,  we asked GOstat  for the GO annotations that  are over-represented in the new domain  
families in comparison with the known domain families. Table 4 lists the results achieved in each 
species for domains certified with an FDR<10%. With the exception of G. lamblia, several terms 
appear to be overrepresented in the different organisms. For example, several overrepresented 
terms are related to DNA- or RNA-binding in Plasmodium species. This finding might be useful 
to decipher the currently debated mode of regulation of transcription in these organisms [26, 27].
Leishmania as a case study
We  emphasized  our  analysis  on  the  genus  Leishmania with  three  species  included  in 
EuPathDomains database. At first glance, we notice that many terms related to DNA and RNA 
stability and transcription are found in the new described domains (Table 4) of these species, in 
comparison with the known ones. This should help to identify novel key elements involved in the 
complex  mechanisms  driving  polycistronic  mRNA transcription  in  Leishmania.  Indeed,  and 
although  extensively  studied,  this  process  remains  one  of  the  major  focuses  of  Leishmania 
biology research [28, 29]. 
First analyses of the predictions achieved in these species show that a great number of newly 
discovered  domains  are  strikingly  shared  between  them  (see  Table  5),  which  increases  our 
confidence in the correctness of the approach. Indeed, the majority of newly discovered domains 
in  L. major (87% with FDR<10%) were also newly discovered in  L. Infantum, while 18 new 
domains were already known in L. infantum species.
When looking to new domain families that were previously unknown in the three Leishmania 
species, 45 domains with an FDR<10% (~40%) are common between them. RQC (PF09382) is 
one of these new domains that are common to the three species. This DNA-binding domain is 
specific to the RecQ family of helicases that bind and unwind G4-DNA. A recently described 
potential  role  [30,  31,  32]  of  this  G4-DNA in  gene  regulation  and  genome  stability  is  its 
participation  in  gene  transcription  by  maintaining  the  DNA in  an  open  conformation  [33].  
Moreover,  RQC  has  a  helix-turn-helix  structure  (HTH)  that  is  commonly  found  in  gene 
regulatory proteins, and known to bind DNA in a sequence-specific manner [34, 35]. RQC could 
thus represent  a relevant feature of Leishmania gene regulatory processes. Related to another 
regulatory level is the “Response reg” domain (PF00072), which is associated in other organisms 
with a “two-component signal transduction system” (TCS) involved in signal transduction events 
[36, 37]. The TCS pathway was originally described in bacteria, and more recently in eukaryotes, 
as involved in sensing the environment for changes in stress or growth conditions [38, 39]. As  
TCS is involved in drug resistance, osmoregulation and motility among others, one can think that 
the  associated  Response_reg  new  domain  could  contribute  to  pathogen  physiological  status 
adaptation to a wide variety of stimuli.
The  new 45  conserved  protein  domains  have  annotations  related  to  different  pathways.  We 
classified them into nine different functional groups based on the pfam2go mapping but also on  
literature mining (Figure 4). The two most represented families are related to transcription and 
DNA binding functions. Besides the existence of all these common domains, a small proportion 
of the new families (16% in  L. major for example) appear to be species specific, even if we 
cannot exclude the possible existence of false positives. As some of these domains may be related 
to species-specific mechanisms (e.g. tropism), they are worth further investigations.
Common new predicted domains between different 
pathogens 
Within EuPathDomains database, eight domain families, which were previously unknown in the 
different  studied pathogens,  are identified in  all  these  organisms.  The presence of these new 
domains addresses the question of their specific occurrence in pathogens and on their potential 
relation with parasitic life style, including common infectious or surviving strategies that have 
already been described for pathogens with various clinical outcomes [40].
In  the  eight  common domain  families,  three  (Utp12,  Utp21  and PWP2)  are  associated  with 
proteins  involved  in  the  small-subunit  (SSU)  processome  for  the  processing  of  the  small-
ribosomal-subunit rRNA [41]. It has been suggested that, through its association with specific 
ribosomal proteins, the SSU processome was probably involved in both pre-rRNA processing and 
ribosome assembly [42]. 
A fourth newly predicted domain family is the polyadenylate-binding protein (PABP)-interacting 
motif PAM2 that has been identified in several eukaryotic proteins, including ataxin-2 [43]. This 
domain interacts with a particular family of RNA helicases and participates in the recognition of 
the  3’end  of  mRNAs,  with  an  essential  contribution  to  eukaryotic  translation  initiation  and 
mRNA stabilization/degradation [44]. In addition, a domain PF08147-DBP10CT corresponding 
to  hypothetical  RNA helicase  has  also  been  identified  in  all  studied  organisms  using  our 
approach. This could reflect the common need for rapid synthesis of molecules favoring survival  
of any organism and its resistance to environmental stress. 
The last three new domains found in all organisms correspond to proteins involved in distinct  
functions. MutS_II is a domain found in the MutS family of proteins involved in mismatch repair  
[45]. Another domain with an unknown function, referenced as PF08953, has been associated in 
Leishmania with the LmjF23.1165 gene, coding for a putative Coronin, a WD-repeat containing 
protein. It is worth noting that the previously described Utp12 and PWP2 domains are members 
of this WD-repeat family. Hence, PF08953 domain might be involved in protein interactions in 
different biological processes such as signal transduction, transcriptional regulation, cytoskeleton 
remodeling, and regulation of vesicle trafficking [46]. Finally, PF09279, a domain called EFhand-
like is newly described in the studied pathogens except Plasmodium species where it was already 
known.  This  domain  is  found  in  the  phosphoinositide-specific  phospholipase  C  family.  The 
phospholipase  activity  has  been  described  as  participating  in  the  degradation  membranes 
containing  pathogens  by  decreasing  the  number  of  phospholipids  causing  the  weakening  of 
membrane integrity [47].
We thus speculate that some of these new domains might be associated to some aspects of the  
parasitic life style. It is therefore now important to explore their occurrence in other organisms.  
Overall, all these new identified protein domains highlight the importance of domain discovery in  
assigning and fine tuning biological functions for poorly, and also for well annotated eukaryotic 
organisms, including important pathogens.  
Conclusion
Domains are the building blocks of proteins and one of the key features to help decipher protein 
function. Indeed, identification of protein domain content is a crucial step in understanding their  
role. HMMs have proved to be a powerful and accurate tool for this purpose, and are the basis of  
the Pfam database, one of the most widely used resources for protein domains. However, these 
models may miss numerous domains in divergent proteins. This is especially true in eukaryotic 
pathogens  where  no  Pfam domains  are  detected  in  more  than  half  of  the  proteins  of  these 
organisms. We recently proposed a method named CODD that uses domain co-occurrence to help 
detect divergent domains. In this paper, this method is applied on ten human eukaryotic parasites.  
All predictions, along with their confidence values and GO annotations, have been integrated in a 
dedicated database named EuPathDomains.
On the whole, the EuPathDomains database significantly improves the domain coverage in all 
genomes,  by  localizing  new  occurrences  of  domains  that  are  already  known  and,  more 
interestingly, by detecting new domain families that have never previously been reported.  For 
example,  with  an  FDR<20%,  EuPathDomains  increases  the  number  of  domain  occurrence 
between 13% to up to 28% in each organism, and the total number of domain families between 
10% to up to 16%. Moreover, several of these new domains also provide new GO annotations.  
Thus, EuPathDomains appears to be a valuable new resource for domain annotation in eukaryotic  
pathogens, and should help deciphering the biology of these complex and crucial organisms.
References
[1] K. Haldar, S. Kamoun, N. L. Hiller, S. Bhattacharje and C. Ooij. Common infection strategies 
of pathogenic eukaryotes. Nature Reviews Microbiology 4 (2006), 922-931.
[1] K. Haldar, S. Kamoun, N. L. Hiller, S. Bhattacharje and C. Ooij. Common infection strategies 
of pathogenic eukaryotes. Nature Reviews Microbiology 4 (2006), 922-931.
[2] Julius P. Kreier.  Infection, resistance and immunity. 2002, Second edition.
[3]  H.  Ochman  and  N.  A.  Moran.  Genes  Lost  and  Genes  Found:  Evolution  of  Bacterial  
Pathogenesis and Symbiosis. Science Vol. 292. no. 5519 (2001), pp. 1096 – 1099.
[4]  Immunology  of  infectious  diseases  Par  Stefan  H.  E.  Kaufmann,Alan  Sher,Rafi  Ahmed 
(Mansfield, 2002)  book chapter  Immune evasion by parsites. J.M. Mansfield and M. Olivier.
[5]  J.  Richardson:  The  anatomy and  taxonomy of  protein  structure.  Adv  Protein  Chem.,  34 
(1981), 167-339.
[6]  H.  Hegyi  and  M.  Gerstein.  Annotation  Transfer  for  Genomics:  Measuring  Functional 
Divergence in Multi-Domain Proteins. Genome Research 11(2001): 1632–1640.
[7]  R.  Finn.  The Pfam protein families  database.  Nucleic  Acids  Research,  36 (2008).  D281- 
D288.
[8] R. Durbin. Biological sequence analysis: probabilistic models of proteins and nucleic acids.  
(1998) Cambridge University Press, Cambridge, UK.
[9] P. Ward1, L. Equinet, J. Packer and C. Doerig. Protein kinases of the human malaria parasite  
Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics, 5 (2004):79.
[10] N. Terrapon, O. Gascuel, É. Maréchal and L. Bréhélin. Detection of new protein domains  
using co-occurrence: application to Plasmodium falciparum. Bioinformatics 2009 25(23):3077-
3083.
[11] G. Apic. Domain combinations in archeal, eubacterial and eukayotic proteomes. J.Mol. Biol.,  
310 (2001).311-325.
[12] C. Aurrecoechea et al., EuPathDB: a portal to eukaryotic pathogen databases. Nucleic Acids 
Research, 38 (2010), Database issue D415-D419.
[13] C. S. Peacock et al, Comparative genomic analysis of three Leishmania species that cause 
diverse human disease. Nature Genetics 39 (2007), 839 - 847
[14] Kooij  TWA, Carlton JM,  Bidwell  SL,  Hall  N, Ramesar J,  et  al,  A Plasmodium Whole-
Genome Synteny Map: Indels and Synteny Breakpoints as Foci for Species-Specific Genes. PLoS 
Pathog vol 1(2005) , No 4, p, 349- 361.
[15]  J.  BLADER and J.  P.  SAEIJ,  communication between Toxoplasma gondii  and  its  host: 
impact on parasite growth, development, immune evasion, and virulence. APMIS 117 (2009), 
p458–476.
[16] Gatei W, Wamae CN, Mbae C, et al. "Cryptosporidiosis: prevalence, genotype analysis, and 
symptoms associated with infections in children in Kenya". Am. J. Trop. Med. Hyg. 75 (2006), 
nu (1): 78–82.
[17]  Abrahamsen  MS,  Templeton  TJ,  et  al.  (2004).  "Complete  genome  sequence  of  the 
apicomplexan, Cryptosporidium parvum." Science 304 (5669): 441–5.
[18]  Svärd  SG,  Meng  TC,  Hetsko  ML,  McCaffery  JM,  Gillin  FD  (December  1998). 
"Differentiation-associated surface antigen variation in the ancient eukaryote Giardia lamblia".  
Molecular Microbiology 30 (5): 979–89.
[19] Tovar J, León-Avila G, Sánchez LB, et al. (2003). "Mitochondrial remnant organelles of  
Giardia function in iron-sulphur protein maturation". Nature 426 (6963): 172–6.
[20] Morrison HG, McArthur AG, Gillin FD, et al. (September 2007). "Genomic minimalism in 
the early diverging intestinal parasite Giardia lamblia". Science 317 (5846): 1921–6.
[21]  F.  Beaussart,  J.  Weiner  and  E.  Bornberg-Bauer.  Automated  Improvement  of  Domain 
ANnotations using context analysis of domain arrangements (AIDAN). Bioinformatics (2007) 
23(14): 1834-1836
[22] N. Mulder et al, New developments in the InterPro database. Nucleic Acids Res. 2007 Jan;  
35(Database issue):D224-8.
[23] S. R. Eddy. Profile hidden Markov models. Bioinformatics. 14(1998):755-63.
[24]  K.  Forslund  and  E.  L.  Sonnhammer.  Predicting  protein  function  from domain  content. 
Bioinformatics; 24 (2008):1681-1687.
[25] T.  Beißbarth and T.  P. Speed.  GOstat:  find statistically overrepresented Gene Ontologies 
within a group of gene; 20 (2004): p 1464-1465.
[26]  K.  Essien,  C.  J.  Stoeckert.  Conservation  and  divergence  of  known  apicomplexan 
transcriptional regulons. BMC Genomics 11 (1) 2010, art. no. 147
[27] E. Bischoff, C. Vaquero. In silico and biological survey of transcription-associated proteins  
implicated in the transcriptional machinery during the erythrocytic development of Plasmodium 
falciparum. BMC Genomics 11 (1) 2010, art no. 34
[28] Haile S, Papadopoulou B. Developmental regulation of gene expression in trypanosomatid 
parasitic protozoa. Curr Opin Microbiol. 10(6):569-77 (2007).
[29]  Clayton C, Shapira M. Post-transcriptional regulation of gene expression in trypanosomes 
and leishmanias. Mol Biochem Parasitol. 156(2):93-101 (2007).
[30] L.A. Hanakahi, H. Sun, N. J. High affinity interactions of nucleolin with G-G-paired rDNA. 
J. Biol Chem, 274 (1999) :15908-15912.
[31] G. N. Parkinson, M. P. Lee, S. Neidle. Crystal structure of parallel quadruplexes from human 
telomeric DNA. Nature, 417 (2002): p876-880.
[32] N. Maizels. Dynamic roles for G4 DNA in the biology of eukaryotic cells Nat Struct and 
Mol Biol, 13 (2006): p1055-1059
[33] Z. Du, Y. Zhao, N. Li.  Genome-wide analysis reveals regulatory role of G4 DNA in gene 
transcription. Genome Res. 18 (2008): 233-241.
[34]  Struhl  K.  Helix-turn-helix,  zinc-finger,  and  leucine-zipper  motifs  for  eukaryotic 
transcriptional regulatory proteins. Trends Biochem Sci. 1989;14(4):137-40.
[35]  K.  Mathee  and G.  Narasimhan.  Detection  of  DNA-Binding  Helix-Turn-Helix  Motifs  in 
Proteins Using the Pattern Dictionary Method. Methods in Enzymology. 2003. 370, 250-264.
[36] G. Krauss. Biochemistry of Signal transduction and regulation. Second Edition. Wiley-VCH, 
2001. Chapter 12. Other Receptor Classes. 377-384.
[37]  G.  M.  Pao,  M.  H.  Saier.  Response  regulators  of  bacterial  signal  transduction  systems:  
selective domain shuffling during evolution. J Mol Evol. 1995. 40(2):136-54.
[38]  J. M Skerker, M. S Prasol, B. S Perchuk, Ee G Biondi, and M. T Laub. Two-Component 
Signal Transduction Pathways Regulating Growth and Cell Cycle Progression in a Bacterium: A 
System-Level Analysis. PLoS Biol. 2005, 3(10): e334.
[39] D.E. Whitworth, P.J Cock. Evolution of prokaryotic two-component systems: insights from 
comparative genomics. Amino Acids. 2009; 37(3):459-66.
[40] Hybiske K and Stephens RS. Exit strategies of intracellular pathogens. Nat Rev Microbiol,  
2008. 6: 99-110.
[41] Dragon F et al., A large nucleolar U3 ribonucleoprotein required for 18S ribosomal RNA 
biogenesis. Nature. 417, 967-970.
[42] Bernstein KA et al., The small-subunit processome is a ribosome assembly intermediate.  
Eukaryot Cell. 2004 Dec;3(6):1619-26.
[43] M. Albrecht, T. Lengauer. Survey on the PABC recognition motif PAM2. Biochem Biophys 
Res Commun. 2004; 316(1):129-38.
[44] Nonhoff et al., 2007. Ataxin-2 Interacts with the DEAD/H-Box RNA Helicase DDX6 and 
Interferes with P-Bodies and Stress Granules. Mol Cell Biol 2007; 18 :1385–1396.
[45] M. H. Lamers, H. H.Winterwerp, T. K. Sixma. The alternating ATPase domains of MutS 
control DNA mismatch repair. EMBO J. 2003; 22(3):746-56.
[46]  P.  J.  Coronin.  Diversity of WD-repeat  proteins.  Subcell  Biochem 2008; 48:116-23 AND 
Smith TF. Subcell Biochem. 2008;48:20-30.
[47] Cummings, B. S., McHowat, J. & Schnellmann, R. G. Phospholipase A2s in cell injury and 
death. J. Pharmacol. Exp. Ther. 294, 793–799 (2000).
 
 
Tables
Table 1: Number of distinct Pfam domains and protein coverage in several  Eukaryotes. 
Column « Pfam domains » lists the number of different known Pfam domains on a given genome. 
Column « Pfam coverage »  gives  the  percentage  of  proteins  with  at  least  one  known  Pfam 
domain.
Organism Proteome size Number of Pfam 
domains
Pfam 
Coverage
Classical eukaryotes
A. gambiae 12347 2991 74%
A. thaliana 34517 3125 74%
C. elegans 22637 2953 65%
D. melanogaster 16224 3129 72%
D. rerio 31884 3384 84%
H. sapiens 40252 3914 68%
S. cerevisae 5862 2369 76%
Eukaryotic pathogens included in EuPathDomains database
P. falciparum 5460 1429 53%
P. vivax 5432 1415 50%
P. yoelii 7724 1313 42%
L. major 8406 1607 49%
L. infantum 8216 1607 49%
L. brazelinsis 8310 1587 48%
T. gondi 8102 1689 43%
G. lamblia 4889 845 49%
C. parvum 3805 1123 51%
T. brucei 9895 1554 38.00%
Table 2: Newly discovered domains in different organisms. “Certif. type” indicates the type of 
certification:  by  known  Pfam  domains  (“Pfam”),  by  known  InterPro  non-Pfam  domains 
(“Interp.”), or by potential domains (“Pot.”); Column “All” lists the results achieved when the 3 
types  of  certifications  were combined.  “Certif.  dom.” denotes  the  number  of  newly  certified 
domains,  “New Interp.”  indicates  the  number  of  certifications  allowing us  to  identify a new 
InterPro Entry for the protein, and “New Dom. Types” indicates the number of domain types that  
were  not  previously  detected  in  any protein  of  the  genome.  In  parentheses  are  reported  the 
proportions of new domains or new domain types in comparison with the number of already 
known domains/types.
FDR ≤ 10% ≤ 20%
Organism Certif. type Pfam Interp. Pot. All Pfam Interp. Pot. All
L. major
Certif. Dom. 231 260 165 423 (8%) 385 417 316 719 (14%)
New Interp. 187 200 143 341 326 333 279 607
New Dom. Types 76 80 48 118 (7%) 104 106 98 184 (11%)
P. falciparum
Certif. Dom. 250 145 50 320(9%) 348 363 130 555 (15%)
New Interp. 192 106 40 241 284 288 114 451
New Dom. Types 64 36 14 80 (6%) 97 92 36 144 (10%)
T. gondii
Certif. Dom. 340 169 126 466 (8%) 436 552 255 776 (13%)
New Interp. 284 138 107 392 379 475 228 671
New Dom. Types 90 49 39 119 (7%) 118 148 67 198 (12%)
C. parvum
Certif. Dom. 292 246 123 417 (21%) 344 379 169 554 (28%)
New Interp. 251 187 103 342 302 313 144 473
New Dom. Types 109 78 42 135 (12%) 131 127 60 182 (16%)
G. lamblia
Certif. Dom. 126 63 18 144 (5%) 303 279 74 386 (13%)
New Interp. 108 54 16 126 279 146 67 357
New Dom. Types 44 23 13 52 (6%) 75 42 25 90 (10%)
T. brucei
Certif. Dom. 348    285 * 120 515 (9%) 513 616 270 908 (16%)
New Interp. 285    201 * 109 418 442 501 243 768
New Dom. Types 73   48 * 29 99 (6%) 111 118 60 176 (11%)
* these results are achieved with an FDR= 12%; no certifications with FDR<10% were achieved 
in T. brucei with the Interpro non-Pfam domains  
Table 3: New GO annotations on different species proteins. “Single Domains” is the number 
of  new GO annotations  supplied  by  a  single  domain  certified  by  our  approach;  “Combined 
domains” is the number of supplementary GO annotations (different from the previous column) 
that can be deduced from combinations of the newly certified domain and another known or new 
domain;  “Unannot.  Prot.”  is  the  number  of  proteins  without  any  annotation  for  which  an 
annotation is now proposed.
Organism FDR Single Domains
Combin. With
Certified Dom.
Unannot.
Prot.
L. major ≤ 10% 158 108 28
≤ 20% 302 164 53
P.  
falciparum
≤ 10% 117 77 20
≤ 20% 250 111 39
T. gondii ≤ 10% 226 129 38
≤ 20% 412 165 71
C. parvum ≤ 10% 176 114 44
≤ 20% 258 141 56
G. lamblia ≤ 10% 51 37 14
≤ 20% 203 99 59
T. brucei ≤ 10%   246* 175   37*
≤ 20% 402 282 79
*: results achieved with an FDR= 12%; no certifications with FDR<10% were achieved in  T. 
brucei with the Interpro non-Pfam domains
Table 4: GO terms that appear as overrepresented in the newly discovered domains for each 
organism compared to  already known ones (black  boxes).  L.  m  for L.  major; P.  f  for P.  
falciparum; T. g for T. gondii; G. l for G. lamblia; C. p for C. parvum and T. b for T. brucei.
 GO term  L. m  P. f  T. g  G. l  C. p T. b
Molecular function
Signal transducer activity  
Protein_kinase activity  
Transmembrane  receptor  protein  kinase 
activity
Zinc ion binding
Purine ribonucleotide binding
ATP binding
Structure specific DNA binding
Enzyme inhibitor activity
GTP binding
Biological process
Post-translational protein modification
Cell communication
Cell surface receptor linked signaling pathway
Signal transduction
DNA replication, synthesis of RNA primer
Glucose catabolic process
Cellular component
Nucleus
Receptor complex
Intracellular membrane-bounded organelle
Clathrin adaptor complex
Phosphopyruvate hydratase complex
Table 5: Proportion of known and new Pfam domains in L. major proteins with a known L.  
infantum homolog  that  are  also  present  in  the  known/new  Pfam  domains  of  their  L.  
infantum homolog. For example, 5279 known Pfam domains are in a  L. major protein with a 
known  L. infantum  homolog. Among these, 5114 are also found in the  L. infantum homolog. 
Similarly, 448 new domains with a FDR<10% in L. major are in proteins with a known homolog 
in L. infantum. Among these, 18 are already known in the L. infantum homolog, and 390 are also 
detected in the L. infantum homologue with an FDR<10%.
L. Infantum
L. 
major
Known 
domains
New dom. 
FDR≤10%
New dom. 
FDR≤20%
Known domains 5114/5279 (97%) 31/5279 (1%) 36/5279 (1%)
New dom. 
FDR≤10%
18/448 (4%) 390/448 (87%) 392/448 (88%)
New dom. 
FDR≤20%
19/776 (2%) 535/776 (69%) 604/776 (78%)
Legend of figures
Figure 1: The CODD certification process. The CDP list was computed from all domain pairs 
found in the UniProt proteins.  The protein sequences were matched against the set of 10 340 
Pfam profile HMMs with loose E-value thresholds to allow detection of more domains. Domains 
overlapping with known Pfam domains were discarded. In the remaining overlaps, domains with 
the best E-value were kept.  The CDP list  was used for the certification process of the set of  
potential  domains.  An  FDR  estimation  process  was  then  carried  out  to  assess  the  level  of  
confidence of the certified domains.
Figure 2: Known and newly predicted domains of  L. major gene LmjF36.4590. One InterPro 
domain is already known (SSF57903). Localization as well as known GO annotation terms are 
given. Three new Pfam domains PF02178, PF00628 and PF00643 are predicted with E-values of 
0.93 and 0.6 and 0.27 respectively. They have been certified by several validating domains with 
various FDRs. For example, the second  domain have been certified by  the known InterPro  
SSF57903 with an FDR equal to 20%, and the potentials Pfam PF02178 and PF00643 with FDRs 
below 10%. New GO terms are transferred to this protein from the predicted Pfam PF00628  
itself: “zinc ion binding” and “protein binding”. The “zinc ion binding” is already known for that  
protein.  Combined with other predicted domains, it brings new annotations such as “regulation 
of transcription, DNA related”.
Figure 3: Comparison of frequency of known (blue) and newly certified (red) L. Major domains 
according to their lengths.
Figure 4: GO functions of common new domain families predicted in L.major,  L. infantum and 
L. braziliensis.
